NEKTAR THERAPEUTICS — Director's Dealing 2016

Feb 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2016-02-10

Reporting Person: Thomsen Jillian B. (SVP & Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-10	Common Stock	M	15000	$6.65	Acquired	18999	Direct
2016-02-10	Common Stock	S	15000	$11.49	Disposed	3999	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-10	Stock Option	$6.65	M	15000	Disposed	2016-03-19	Common Stock (15000)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in early 2016 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015.

F2: This transaction was executed in multiple trades at prices ranging from $11.16 to $11.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.